



PHARMACOG

Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development

IRCCS Istituto Centro San Giovanni di Dio - Fatebenefratelli

Moira Marizzoni

email

mmarizzoni@fatebenefratelli.eu

09/08/2022

1 Collaborating Centers

- IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli (Brescia)
- Center for Mind Brain Sciences, University of Trento, Trento, Italy
- General Hospital, Verona, Italy
- University “G. d’Annunzio” of Chieti, Chieti, Italy
- Perugia General Hospital, Perugia, Italy
- Catholic University, Rome, Italy
- University of Genoa, Genoa, Italy
- IRCCS SDN, Naples, Italy
- IRCCS AOU San Martino, Genoa, Italy
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy
- University of Rome, Rome, Italy
- Clínic de Barcelona, IDIBAPS, Barcelona, Spain
- Universitat de Barcelona and IDIBAPS, Barcelona, Spain
- Aristotle University of Thessaloniki, Thessaloniki, Greece
- Alzheimer Centre, VU Medical Centre, Amsterdam, Netherlands
- University of Leipzig, Leipzig, Germany
- University of Duisburg-Essen, Essen, Germany
- University of Lille, INSERM U1171, Memory Clinic, Lille, France
- University Hospital, Lille, France
- Aix-Marseille Université, INSERM U 1106, 13005 Marseille, France
- Université de Toulouse, Toulouse, France
- UMR CNRS-Universite de la Mediterranee, Marseille, France
- Qualissima, Marseille, France

2 Cohort Description

Age Range: 55-90

Size N: 147 subjects

Recruitment: december 2011 - june 2013

Data collection: 2011-2015

Healthy controls: no

Only at-risk gene carriers included: no

Diseases studied: Mild Cognitive Impairment (MCI)

Clinical Evaluation:

- Neuropsychological Assessments (tests performed): the Alzheimer's Disease Assessment Scale, cognitive portion (ADAS-Cog), MMSE, ReyAuditory Verbal Learning Test (RAVLT), logical memory, clock drawing test, trail making test forms A and B, digit span forward and backward, WAIS-R digit symbol substitution test, letter and category fluency test and Boston naming test. Validated test versions were available in different languages. Some tests of the computerized Cambridge Neuropsychological Test Automated Battery (CANTAB) were administered to assess visual memory [paired-associates learning (PAL), delayed matching to sample (DMS), pattern recognition memory (PRM) and spatial recognition memory (SRM)], working memory [spatial working memory (SWM)] and attention [reaction time (RT) and rapid visual information processing (RVP)]
- Behavioural Assessments (tests performed): Nottingham Extended ADL Scale, Everyday cognition scale, Cognitive Function Instrument, Independent Living Skills Survey, Hollingshed, Beck Cognitive Insight Scale, Anosognosia Questionnaire-Dementia, Neuropsychiatric Inventory, Starkstein Apathy Scale, Symptom Checklist-90-R, Structured Interview for Prodromal Syndromes, Cerad Disphoria, Hamilton Anxiety Rating Scale, Hamilton Depression Rating Scale, Coping Orientation to Problems Experienced – Brief, Resilience Scale for Adult

Imaging and Neurophysiology:

- EEG
- MRI 3 T

Genotyping: APOE

Digital Data obtained from patients through electronic devices: yes

Biological Samples:

- CSF (abeta 42, tau, p-tau)

Follow-up:

- Number of Follow-ups completed: 590
- Average duration between follow-ups (years): 0.5 years (6 months)
- Follow-ups type: Clinical evaluation, EEG, MRI

Data Storage: NeuGRID2